Neil Macallister Joins Inc Research Board of Directors
03 January 2006
RALEIGH, N.C. – September 22, 2005 - INC Research®, a global contract research organization (CRO) specialized in central nervous system (CNS), oncology and pediatric clinical research, announced today that Neil MacAllister has joined its board of directors.
Mr. MacAllister serves as the CEO and President of AVOS Life Sciences, a boutique research products and advisory firm in the healthcare environment. He has an extensive background in strategic management within the pharmaceutical and biotechnology industries. Prior to founding AVOS, Mr. MacAllister was Executive Vice President of Corporate Development at Quintiles Transnational, where he was responsible for strategic development and planning, including management of corporate business development, corporate marketing, and sales support functions. Mr. MacAllister served as Managing Director for the Wilkerson Group, a leading pharmaceutical consultancy firm later acquired by IBM. Mr. MacAllister has also held various executive and consulting positions with such firms as Booz Allen & Hamilton, Wood MacKenzie and Beecham International.
"Neil MacAllister is an excellent addition to INC Research’s Board of Directors," said Jim Ogle, CEO of INC Research. "With over 20 years in the life science sector, Neil brings INC Research a depth of leadership experience and global industry knowledge. His unique expertise in delivering strategic, operational, and financial insights to decision makers in the life sciences will be invaluable as we advance our strategic business initiatives, which center on enhancing the value and quality of service provided in support of our customers."
"INC Research has sustained impressive growth over the last several years," stated Mr. McAllister. "It clearly demonstrates that its high performance teams have delivered a level of expertise and service demanded in the competitive and complex areas of CNS and oncology drug development. INC Research has proven that it is a key player in the CRO sector. The company is poised for continued success, and I look forward to participating in the process."
